I am a healthy and fit 55-year-old woman. My bone density test showed that I needed to be supplemented. I cannot take hormones as I had a blood clot, so the doctor prescribed Fosamax. I had awful side effects: muscle pain, joint pain, etc. He has now prescribed Forteo. Is this a good alternative?
I have had painful periods for the past couple of years and have also had ovarian cysts. I had a couple of larger cysts removed about five years ago and was told I had endometriosis at that time. I continue to have pain and now have been told I have a 7 cm cyst on the right ovary. My doctor recommends removing both ovaries and the uterus. I'm just researching the pros and cons. Was wondering if there are any major issues I should be concerned about if I had the uterus and both ovaries removed. I am 42 and do not plan to have children. Given the history of pain and previous cysts, is it a good idea to go ahead and remove everything? Thanks for your time. Melissa
Women who have used the bone-building drug Fosamax are nearly twice as likely to develop the most common kind of chronically irregular heartbeat as those who have never used it. Patients, especially those with family history of heart problems, should talk to their doctor about whether the drug is the appropriate option for them. The study was published in the Archives of Internal Medicine in April 2008.
After the latest round of mixed earnings from the biggest players in pharma and biotech, companies are hampered by a frustrating dynamic: a product mix that isn't strong enough to match an exodus of blockbusters.
What we said In "Merck Is on the Mend" (Feb. 5), we recommended a second look at the pharma giant, which was recovering from the low it reached in 2004 amid the Vioxx debacle. We mentioned that Merck was winning approvals for a host of new drugs, including cervical-cancer vaccine Gardasil. We cited Bear Stearns analyst John Boris's year-end price target of $53.
Merck posted a 62 percent increase in its third-quarter profit Monday, as the drugmaker's revenues increased by double digits, while lower administration and overhead costs offset more spending on research and development.
The successful launch of a blockbuster drug depends heavily on Big Pharma's ability to custom-tailor its sales pitch country-by-country, a difficult task in which few drugmakers excel, according to a study from research firm IMS Health.
The multi-billion dollar drug industry for degenerative bone disease is getting more congested, with new studies showing the benefits of the Novartis drug Aclasta, and an experimental drug from Amgen on the way.
With at least seven competing drugs shouldering in, the multi-billion dollar market for treating elderly bones is getting crowded. There will probably be enough aging baby boomers to go around ... but expect some jostling.